Evidence map›Paper›PMID 1998656›Full record

Trial reportArteriosclerosis and thrombosis : a journal of vascular biology

Evaluation of human panelists in assessing coronary atherosclerosis.

S P Azen, L Cashin-Hemphill, J Pogoda, W J Mack, M E Sanmarco, E Wickham, D H Blankenhorn

Registry-linked trialOpen access · bronzeAbstract readClinical TrialRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Arteriosclerosis and thrombosis : a journal of vascular biology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT00000599. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
4.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00000599 phase3completed

Cholesterol-Lowering Atherosclerosis Study (CLAS)

Ran1980Registered outcomes0Posted comparisons0ConditionsArterial Occlusive Diseases, Atherosclerosis, Cardiovascular Diseases, Carotid Artery DiseasesArmscolestipol, diet, fat-restricted, niacin
Open the trial in the graph
3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 19 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

S P AzenDepartment of Preventive Medicine, University of Southern California, Los Angeles.
L Cashin-Hemphill
J Pogoda
W J Mack
M E Sanmarco
E Wickham
D H Blankenhorn
National Heart Lung and Blood Institute · USUniversity of Southern California · USThrombosis and Atherosclerosis Research Institute · CA

Funding

NHLBI NIH HHS R01-HL-23619
6 · The paper itself

Abstract

The Cholesterol Lowering Atherosclerosis Study, a randomized, angiographic clinical trial, has demonstrated the beneficial effect of niacin/colestipol therapy on coronary and femoral atherosclerosis. The primary outcome was a panel-determined consensus score evaluating global coronary changes determined angiographically at 2 years. This article presents an evaluation of interreader agreement in independently assessing the status of native coronary arteries and overall coronary condition. Parameters include 1) identification of the presence of lesions and lesion changes; 2) estimation of lesion severity (percent stenosis) and amount of change in lesion severity; and 3) global assessment of change in coronary status. Readers independently agreed on 1) presence of lesions (82%) and change in lesions (51%); 2) percent stenosis +/- 10% (76%) and change in stenosis +/- 10% (81%); and 3) global assessment of change in coronary status within one step (96%). Results of these analyses may be useful in effectively designing angiographic trials that use a panel of human evaluators as well as computerized methods for angiographic interpretation.

Indexed as

Coronary AngiographyAdultArteriosclerosisClinical Trials as TopicColestipolHumansMaleMiddle AgedNiacinObserver VariationReproducibility of ResultsColestipolNiacin

Identifiers

PMID1998656
OpenAlexW2156126800

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.